



Australian Government
Department of Health
 Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	232541	Ki Cold and (&) Flu Attack
ARTG entry for	Medicine Listed	
Sponsor	Martin & Pleasance Pty Ltd	
Postal Address	PO Box 2007, SOUTH MELBOURNE, VIC, 3205 Australia	
ARTG Start Date	12/01/2015	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . Ki Cold and (&) Flu Attack

Product Type	Effective Date
Single Medicine Product	22/01/2020

Permitted Indications

- Traditionally used in Chinese medicine to dispel/expel/disperse/clear external/exogenous wind
- Maintain/support general health and wellbeing
- Traditionally used in Western herbal medicine to antipyretic/febrifuge/relieve mild fever/reduce body temperature/body cooling
- Traditionally used in Chinese medicine to decrease/reduce/relieve symptoms of allergic rhinitis
 - Linked indication - Helps decrease/reduce/relieve facial tenderness associated with allergic rhinitis
 - Linked indication - Relieve runny/dripping nose
 - Linked indication - Anti-inflammatory/relieve inflammation
- Enhance/improve/promote immune defence/immunity
- Maintain/support healthy immune system function
- Maintain/support (state vitamin/mineral/nutrient) levels in the body
- Traditionally used in Chinese medicine to decrease/reduce/relieve headache symptoms
 - Linked indication - Decrease/reduce headache duration
 - Linked indication - Analgesic/Anodyne/relieve pain
- Decrease/reduce/relieve common cold duration
- Helps decrease/reduce/relieve the severity of symptoms of common colds and flu
- Traditionally used in Chinese medicine to decrease/reduce/relieve symptoms of common colds and flu
 - Linked indication - Decongestant/relieve nasal congestion
 - Linked indication - Decrease/reduce excess chest phlegm
 - Linked indication - Decrease/reduce/relieve cough
 - Linked indication - Relieve runny/dripping nose
 - Linked indication - Antipyretic/febrifuge/relieve mild fever/reduce body temperature/body cooling
 - Linked indication - Relieve eye redness
- Decrease/reduce/relieve the severity of symptoms of mild upper respiratory tract infections

Public Summary



Australian Government
Department of Health
 Therapeutic Goods Administration

- Linked indication - Helps reduce occurrence of symptoms of headaches
- Linked indication - Decrease/reduce/relieve disturbed/restless sleep
- Linked indication - Expectorant/clear respiratory tract mucous
- Linked indication - Decrease/reduce/relieve cough
- Linked indication - Relieve runny/dripping nose
- Linked indication - Decrease/reduce/relieve mild throat inflammation
- Linked indication - Decrease/reduce/relieve throat irritation
- Linked indication - Relieve weariness/tiredness/fatigue/feeling of weakness
- Linked indication - Relieve feelings of general malaise/general debility
- Linked indication - Antipyretic/febrifuge/relieve mild fever/reduce body temperature/body cooling
- Traditionally used in Chinese medicine to relieve symptoms of sore throat/pharyngitis
- Linked indication - Decrease/reduce/relieve mild throat inflammation
- Linked indication - Antipyretic/febrifuge/relieve mild fever/reduce body temperature/body cooling
- Linked indication - Analgesic/Anodyne/relieve pain

Indication Requirements

- Label statement: If symptoms persist, talk to your health professional.
- Product presentation must not imply or refer to serious forms of respiratory disorders/diseases, such as: asthma, pneumonia, COAD, COPD, influenza.
- Label statement: Adults only, OR Not to be used in children under 2 years of age without medical advice (or words to that effect).
- Product presentation must not imply or refer to serious immunological diseases.
- If TCM terminology is used on medicine label, label statement: Talk to a TCM practitioner/health professional if you are unsure if this medicine is right for you.
- Label statement: Not to be used in children under 5 years.
- Respiratory tract infections must be qualified by 'mild'.
- Product presentation must not imply or refer to chronic fatigue syndrome.
- Product presentation must not imply or refer to mental illnesses, disorders or conditions.
- Product presentation must not imply or refer to serious allergic conditions such as anaphylaxis.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

Adults only. OR Not to be used in children under two years of age without medical advice (or words to that effect).

Additional Product information

Pack Size/Poison information

Pack Size	Poison Schedule
-----------	-----------------

Components

1 . Formulation 1

Dosage Form	Tablet, film coated
Route of Administration	Oral

Visual Identification

Active Ingredients

Andrographis paniculata	100 mg
zinc amino acid chelate	30 mg
Equivalent: zinc	6 mg
Zingiber officinale rhizome Extract dry concentrate	150 mg
Equivalent: Zingiber officinale (Fresh)	1.5 g

Other Ingredients (Excipients)

- calcium carbonate
- calcium hydrogen phosphate dihydrate
- Carnauba Wax
- colloidal anhydrous silica
- croscarmellose sodium
- curcumin

Public Summary



Australian Government

Department of Health
Therapeutic Goods Administration

hypromellose
macrogol 400
magnesium stearate
microcrystalline cellulose

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary